The NMP22®
BladderChek Test is the only in-office test approved by the FDA
for the diagnosis of bladder cancer.
The NMP22
BladderChek Test is a painless and non-invasive assay, performed
on a single urine sample, that detects elevated levels of NMP22
protein. Healthy individuals generally have very small amounts
of NMP22 protein in the urine. However, the level of NMP22
protein is often elevated in the urine of patients with bladder
cancer, even at early stages of the disease.
The test can be
performed in a physician’s office with results delivered during
the patient visit, allowing a rapid, accurate and cost-effective
way to aid in the detection of bladder cancer in patients at
risk.
The use of the NMP22 protein has been FDA-approved four times
for various formats and claims, most recently in April 2003 for
point-of-care use for diagnosis.
» Click
here to visit NMP22 Product website.
» For quantitative ELIZA KITS
click here.
